MAP Kinase Pathway Alterations in BRAF -Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
Nikhil Wagle, Eliezer M. Van Allen, Daniel J. Treacy et al. · Cancer Discovery · 2013
Abstract Treatment of BRAF-mutant melanoma with combined dabrafenib and trametinib, which target RAF and the downstream MAP–ERK kinase (MEK)1 and MEK2 kinases, respectively, improves progression-free survival and response rates compared with dabrafenib monotherapy. Mechanisms of clinical resistance to combined RAF/MEK inhibition are unknown. We performed whole-exome sequencing (WES) and whole-transcriptome sequencing (RNA-seq) on pretreatment and drug-resistant tumors from five patients with acquired resistance to dabrafenib/trametinib. In three of these patients, we identified additional mitogen-activated protein kinase (MAPK) pathway alterations in the resistant tumor that were not detected in the pretreatment tumor, including a novel activating mutation in MEK2 (MEK2Q60P). MEK2Q60P conferred resistance to combined RAF/MEK inhibition in vitro, but remained sensitive to inhibition of the downstream kinase extracellular signal–regulated kinase (ERK). The continued MAPK signaling-based resistance identified in these patients suggests that alternative dosing of current agents, more potent RAF/MEK inhibitors, and/or inhibition of the downstream kinase ERK may be needed for durable control of BRAF-mutant melanoma. Significance: This study represents an initial clinical genomic study of acquired resistance to combined RAF/MEK inhibition in BRAF-mutant melanoma, using WES and RNA-seq. The presence of diverse resistance mechanisms suggests that serial biopsies and genomic/molecular profiling at the time of resistance may ultimately improve the care of patients with resistant BRAF-mutant melanoma by specifying tailored targeted combinations to overcome specific resistance mechanisms. Cancer Discov; 4(1); 61–8. ©2013 AACR. See related commentary by Solit and Rosen, p. 27 This article is highlighted in the In This Issue feature, p. 1
Cited by 477 works. doi:10.1158/2159-8290.cd-13-0631
Authors
- Nikhil Wagle
- Eliezer M. Van Allen
- Daniel J. Treacy
- Dennie Tompers Frederick
- Zachary Aaron Cooper
- Amaro N Taylor-Weiner
- Mara W. Rosenberg
- Eva M. Goetz
- Ryan Joseph Sullivan
- Deborah Norman Farlow
- Dennis C. Friedrich
- Kristin Anderka
- Danielle Perrin
- Cory M. Johannessen
- Aaron McKenna
- Kristian Cibulskis
- Gregory V. Kryukov
- Eran Hodis
- Donald P. Lawrence
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)